Login Register

New state-of-the-art hair loss treatment for cancer patients at CircleBath

By Anna_Garside  |  Posted: February 26, 2013

Comments (1)

A new state-of-the-art treatment to prevent hair loss during chemotherapy is being offered to cancer patients at CircleBath Hospital. 

The cancer treatment specialist nurses at CircleBath chose the DigniCap system after personally trying a number of other available methods and deciding that it was the best treatment option for their patients due to its comfort and clinical results.

The hair-loss treatment is available for CircleBath Hospital patients in Bath and surrounding communities.

Sandra Jones, lead nurse for CircleBath Hospital Oncology, said: ""We researched, deliberated and compared clinical and technical aspects of several scalp-cooling treatments before making our final decision. Then we decided that we needed to try the caps ourselves before offering them to our patients.  DigniCap was eminently more comfortable and user-friendly. Add to that the assurance of clinically proven safety, and there was really no debate." 

The system, developed by Dignitana, a world leader in scalp-cooling technology, is a safe, gentle and effective treatment for avoiding hair loss related to chemotherapy. It continuously monitors temperature to ensure comfort and consistent application of the treatment. Caps are specifically designed so that the ears remain uncovered for added comfort and normal hearing during the process.

DigniCap is the first scalp cooling system that can be offered with temperatures above freezing, which makes for a less stressful and more comfortable treatment.

For more information about the DigniCap System offered at Circle Health's CircleBath Hospital please email: enquiries@circlebath.co.uk.

Read more from Western Daily Press

Do you have something to say? Leave your comment here...

max 4000 characters
  • siarad2  |  February 26 2013, 8:32PM

    Eskimo have a saying 'head warm all warm' so head cold...

    Rate   1
    Report

      YOUR COMMENTS AWAITING MODERATION

       
       

      MORE NEWS HEADLINES